Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2021-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study objectives are to assess the safety and efficacy of the CoreValve Evolut 34R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis who are considered at high or extreme risk for surgical aortic valve replacement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medtronic CoreValve Evolut R U.S. Clinical Study

NCT02207569

Aortic Stenosis

COMPLETED NA

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

NCT02701283

Aortic Valve Stenosis

ACTIVE_NOT_RECRUITING NA

The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study

NCT01876420

Aortic Stenosis

COMPLETED NA

CoreValve™ Evolut R™ FORWARD Study

NCT02592369

Aortic Valve Stenosis

COMPLETED

CoreValve™ Evolut R™ 34 mm System Registry (CoreValve34)

NCT03621709

Aortic Valve Stenosis Transcatheter Aortic Valve Implantation

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This objective will be accomplished by a prospective, single arm, historical controlled, multi-site study involving up to 60 implanted subjects at up to 15 study sites in the United States. Procedural and 30 day safety and efficacy results from this study will be compared to appropriate historical control data for the Medtronic CoreValve System. Subjects will be followed up to 5 years following implantation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CoreValve Evolut 34R TAVR system

Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.

Group Type EXPERIMENTAL

CoreValve Evolut 34R TAVR system

Intervention Type DEVICE

The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:

1. Evolut 34R Transcatheter Aortic Valve (TAV)
2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
3. EnVeo R Loading System (LS)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CoreValve Evolut 34R TAVR system

The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:

1. Evolut 34R Transcatheter Aortic Valve (TAV)
2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
3. EnVeo R Loading System (LS)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Severe aortic stenosis, defined as aortic valve area of \< 1.0 cm2 (or aortic valve area index of \< 0.6 cm2/m2) by the continuity equation, AND mean gradient \> 40 mmHg or maximal aortic valve velocity \> 4.0 m/sec by resting echocardiogram.

Subjects with low-flow/low gradient severe aortic stenosis can be included, provided low-dose dobutamine or exercise stress echocardiography demonstrates a mean gradient of \> 40 mmHg or a maximal aortic valve velocity of \> 4.0 m/sec, AND aortic valve area of \< 1.0 cm2 (or aortic valve area index of \< 0.6 cm2/m2).
2. Society of Thoracic Surgeons (STS) score of ≥ 8 OR documented heart team agreement of ≥ high risk for aortic valve replacement due to frailty or co-morbidities.
3. Symptoms of aortic stenosis, AND New York Heart Association (NYHA) Functional Class II or greater.
4. The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria

5. Any condition considered a contraindication for placement of a bioprosthetic valve (e.g. subject is indicated for mechanical prosthetic valve).
6. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:

* aspirin or heparin (HIT/HITTS) and bivalirudin
* ticlopidine and clopidogrel
* Nitinol (titanium or nickel)
* contrast media
7. Blood dyscrasias as defined: leukopenia (WBC \< 1000 mm3), thrombocytopenia (platelet count \<50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states.
8. Untreated clinically significant coronary artery disease requiring revascularization.
9. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) \< 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.
10. End stage renal disease requiring chronic dialysis or creatinine clearance \< 20 cc/min.
11. Ongoing sepsis, including active endocarditis.
12. Any percutaneous coronary or peripheral interventional procedure with a bare metal or drug eluting stent performed within 30 days prior to study procedure.
13. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 10 weeks of Heart Team assessment.
14. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
15. Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
16. Gastrointestinal (GI) bleeding that would preclude anticoagulation.
17. Subject refuses a blood transfusion.
18. Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
19. Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions.
20. Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-ups exams.
21. Currently participating in an investigational drug or another device study (excluding registries).
22. Evidence of an acute myocardial infarction ≤ 30 days before the study procedure.
23. Need for emergency surgery for any reason.
24. Liver failure (Child-Pugh class C).
25. Subject is pregnant or breast feeding.

26. Pre-existing prosthetic heart valve in any position.
27. Mixed aortic valve disease (aortic stenosis with severe aortic regurgitation).
28. Severe mitral regurgitation.
29. Severe tricuspid regurgitation.
30. Moderate or severe mitral stenosis.
31. Hypertrophic obstructive cardiomyopathy.
32. Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac mass, thrombus, or vegetation.
33. Congenital bicuspid or unicuspid valve verified by echocardiography.

For transfemoral or transaxillary (subclavian) access:
34. Access vessel diameter \< 5.5 mm or \<6.0 mm for patent left internal mammary artery (LIMA)

Eligible Sex

ALL

Accepts Healthy Volunteers

No